Provided by Tiger Trade Technology Pte. Ltd.

Eloxx Pharmaceuticals (Uplisting)

20.98
+2.9416.27%
Post-market: 20.980.00000.00%19:37 EDT
Volume:93.39K
Turnover:2.00M
Market Cap:84.66M
PE:-7.36
High:23.40
Open:19.00
Low:18.04
Close:18.04
52wk High:23.40
52wk Low:0.0000
Shares:4.04M
Float Shares:2.39M
Volume Ratio:2.35
T/O Rate:3.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8493
EPS(LYR):-183.1293
ROE:-615.23%
ROA:-97.59%
PB:1.82
PE(LYR):-0.11

Loading ...

Oct 14, 2022

Major Issues Report

8-K - Current report
Sep 15, 2022

Major Issues Report

8-K - Current report
Aug 15, 2022

Major Issues Report

8-K - Current report
Aug 12, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 15, 2022

Major Issues Report

8-K - Current report
Jul 05, 2022

Major Issues Report

8-K - Current report
Jun 16, 2022

Major Issues Report

8-K - Current report
May 10, 2022

Major Issues Report

8-K - Current report
May 06, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Apr 04, 2022

Major Issues Report

8-K - Current report
Mar 30, 2022

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 03, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Jan 05, 2022

Major Issues Report

8-K - Current report
Dec 03, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Dec 03, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Dec 03, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Dec 01, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Sep 13, 2021

Major Issues Report

Eloxx Pharmaceuticals, Inc.
Sep 13, 2021

Major Issues Report

8-K - Current report